MARKSANS — Marksans Pharma Cashflow Statement
0.000.00%
- IN₹80.23bn
- IN₹76.59bn
- IN₹26.23bn
- 63
- 20
- 14
- 19
Annual cashflow statement for Marksans Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3,022 | 2,475 | 3,377 | 4,235 | 5,040 |
| Depreciation | |||||
| Non-Cash Items | 421 | -94.7 | 224 | -188 | -140 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2,017 | -1,836 | -1,745 | -2,485 | -3,667 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,787 | 993 | 2,374 | 2,304 | 2,067 |
| Capital Expenditures | -464 | -463 | -536 | -2,088 | -1,729 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 15.3 | -381 | -2,056 | 680 | 1,239 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -449 | -844 | -2,592 | -1,408 | -490 |
| Financing Cash Flow Items | -79.9 | -42.2 | -60.7 | -51.7 | -23.9 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -153 | 795 | 1,978 | -687 | -651 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,186 | 944 | 1,760 | 208 | 925 |